dht igf1 Search Results


dht igf1  (MedChemExpress)
95
MedChemExpress dht igf1
IGFBP5 supplementation improves endometrial receptivity in PCOS‐derived endometrium. (A) Relative expression of IGFBP5 in proliferative and secretory endometrium of control women, n = 8 per group; (B) Representative immunohistochemistry staining of IGFBP5 in human endometrium of proliferative and secretory phase of control women, scale bars: 50 µm; (C) Quantitative analysis of IGFBP5 protein levels in epithelial and stromal cells of proliferative and secretory endometrium of control women, n = 3 per group; (D) Relative expression of IGFBP5 in secretory endometrium from the CON and PCOS groups, n = 8 per group; (E‐F) Representative immunohistochemistry staining (E) and its quantitative analysis (F) of IGFBP5 protein levels in the secretory endometrium from the CON and PCOS groups, n = 6 per group, scale bars: 50 µm; (G) IGFBP5 mRNA levels in DHT‐treated Ishikawa cells, n = 3 per group; (H) The percentage of JAr spheroids that adhere to Ishikawa cells treated with DHT (0.5 µM), DHT + IGFBP5 (100 ng/ml), DHT + <t>IGF1</t> (50 ng/ml), DHT + IGFBP5 + IGF1 and DHT + IGFBP5 + NVP‐AEW541 (10 µM), n = 3 per group. For A, C, D, F, G, and H, data are presented as mean ± SEM. For A, C, D, and F, the P value was determined by a two‐tailed Student's t ‐test; for G and H, the P value was determined by one‐way ANOVA with Tukey's multiple comparison post hoc test. For B and E, the experiments were performed in three replicates; le, luminal epithelium; ge, glandular epithelium; s, stroma.
Dht Igf1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dht+igf1/IGF-I%2FIGF-1%2C+Human/pmc13170201-194-30-36
Average 95 stars, based on 1 article reviews
dht igf1 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


IGFBP5 supplementation improves endometrial receptivity in PCOS‐derived endometrium. (A) Relative expression of IGFBP5 in proliferative and secretory endometrium of control women, n = 8 per group; (B) Representative immunohistochemistry staining of IGFBP5 in human endometrium of proliferative and secretory phase of control women, scale bars: 50 µm; (C) Quantitative analysis of IGFBP5 protein levels in epithelial and stromal cells of proliferative and secretory endometrium of control women, n = 3 per group; (D) Relative expression of IGFBP5 in secretory endometrium from the CON and PCOS groups, n = 8 per group; (E‐F) Representative immunohistochemistry staining (E) and its quantitative analysis (F) of IGFBP5 protein levels in the secretory endometrium from the CON and PCOS groups, n = 6 per group, scale bars: 50 µm; (G) IGFBP5 mRNA levels in DHT‐treated Ishikawa cells, n = 3 per group; (H) The percentage of JAr spheroids that adhere to Ishikawa cells treated with DHT (0.5 µM), DHT + IGFBP5 (100 ng/ml), DHT + IGF1 (50 ng/ml), DHT + IGFBP5 + IGF1 and DHT + IGFBP5 + NVP‐AEW541 (10 µM), n = 3 per group. For A, C, D, F, G, and H, data are presented as mean ± SEM. For A, C, D, and F, the P value was determined by a two‐tailed Student's t ‐test; for G and H, the P value was determined by one‐way ANOVA with Tukey's multiple comparison post hoc test. For B and E, the experiments were performed in three replicates; le, luminal epithelium; ge, glandular epithelium; s, stroma.

Journal: Advanced Science

Article Title: IGFBP5 Restores Endometrial Receptivity and Rescues Implantation Failure in Polycystic Ovary Syndrome

doi: 10.1002/advs.202520455

Figure Lengend Snippet: IGFBP5 supplementation improves endometrial receptivity in PCOS‐derived endometrium. (A) Relative expression of IGFBP5 in proliferative and secretory endometrium of control women, n = 8 per group; (B) Representative immunohistochemistry staining of IGFBP5 in human endometrium of proliferative and secretory phase of control women, scale bars: 50 µm; (C) Quantitative analysis of IGFBP5 protein levels in epithelial and stromal cells of proliferative and secretory endometrium of control women, n = 3 per group; (D) Relative expression of IGFBP5 in secretory endometrium from the CON and PCOS groups, n = 8 per group; (E‐F) Representative immunohistochemistry staining (E) and its quantitative analysis (F) of IGFBP5 protein levels in the secretory endometrium from the CON and PCOS groups, n = 6 per group, scale bars: 50 µm; (G) IGFBP5 mRNA levels in DHT‐treated Ishikawa cells, n = 3 per group; (H) The percentage of JAr spheroids that adhere to Ishikawa cells treated with DHT (0.5 µM), DHT + IGFBP5 (100 ng/ml), DHT + IGF1 (50 ng/ml), DHT + IGFBP5 + IGF1 and DHT + IGFBP5 + NVP‐AEW541 (10 µM), n = 3 per group. For A, C, D, F, G, and H, data are presented as mean ± SEM. For A, C, D, and F, the P value was determined by a two‐tailed Student's t ‐test; for G and H, the P value was determined by one‐way ANOVA with Tukey's multiple comparison post hoc test. For B and E, the experiments were performed in three replicates; le, luminal epithelium; ge, glandular epithelium; s, stroma.

Article Snippet: Before co‐cultured with JAr spheroids, Ishikawa cells were primed under serum‐free conditions for 24 h with DHT (0.5 μM), DHT + IGFBP5 (100 ng/mL, HY‐ P72378 , Med Chem Express), DHT + IGF1 (50 ng/mL, HY‐P7018, Med Chem Express), DHT + IGFBP5 + IGF1, or DHT + IGFBP5 + NVP‐AEW541 (10 μM, HY‐50866, Med Chem Express) to eliminate interference from serum‐derived factors.

Techniques: Derivative Assay, Expressing, Control, Immunohistochemistry, Staining, Two Tailed Test, Comparison